Loading organizations...
Biotechnology company developing precision medicines for kinase-driven diseases.
Kinaset Therapeutics develops inhaled therapeutic agents, with its primary focus on KN-002, also known as frevecitinib. This lead clinical candidate is a novel, pan-JAK inhibitor designed as a dry powder for oral inhaled delivery, aiming to provide a non-invasive anti-inflammatory treatment for severe asthma. The company's technical approach centers on delivering potent therapeutics directly to the site of inflammation to address a broad range of severe respiratory conditions.
The company was founded in 2020 by Robert Clarke, PhD, who serves as CEO, alongside Roger Heerman, MBA, and Frazer Morgan. This leadership team brings extensive experience in respiratory drug development. Their insight stemmed from the critical need for more effective and broadly applicable treatments for severe respiratory diseases, leading them to pursue a unique inhaled pan-JAK inhibitor strategy.
Kinaset Therapeutics' product is intended for patients suffering from severe asthma, particularly those whose conditions remain inadequately controlled by existing therapies. The company’s long-term vision is to establish a new paradigm in treating respiratory diseases by developing innovative inhaled therapeutics that address significant unmet medical needs, ultimately improving outcomes for a wide spectrum of patients.
Kinaset Therapeutics has raised $143.0M across 2 funding rounds.
Kinaset Therapeutics has raised $143.0M in total across 2 funding rounds.
Kinaset Therapeutics is a clinical-stage biopharmaceutical company developing inhaled therapeutics, primarily KN-002, a treatment for all patients with severe asthma regardless of inflammation cause, and frevecitinib for conditions like chronic obstructive pulmonary disease (COPD).[1][2][4][5] It targets unmet needs in respiratory diseases by creating small molecule drugs, such as JAK1 inhibitors delivered via inhalation, serving patients with severe asthma and pulmonary diseases.[1][2][4] The company solves limitations of existing therapies by offering pan-inflammatory treatments, with growth momentum shown by advancing toward clinical trials (Phase 1 for frevecitinib) since its 2021 founding.[2][3][4][5]
Kinaset Therapeutics Ltd was incorporated on September 6, 2021, as a private limited company in London, with its registered office at 71-75 Shelton Street, Covent Garden.[3] It was co-founded by Robert Clarke, PhD (CEO and Board Member), Roger Heerman, MBA (Chief Business/Operating Officer), and Frazer Morgan (Chief Development Officer), who bring significant respiratory drug development experience.[1] The idea emerged from this team's expertise, supported by scientific advisors like Professors Ian Adcock and Dave Singh, leading to early pivotal moments such as initiating clinical trials for inhaled candidates like frevecitinib (JAK1/JAK2/JAK3/TRPV1 inhibitor) starting July 30, 2021.[1][4]
Kinaset rides the trend of precision respiratory therapeutics amid rising demand for inhaled biologics and small molecules tackling chronic diseases like severe asthma and COPD, where inflammation heterogeneity limits current options.[1][2][4] Timing aligns with post-2021 biotech funding recovery and advances in JAK inhibitors, bolstered by market forces like aging populations and post-pandemic respiratory focus.[4][5] It influences the ecosystem by pioneering pan-inflammatory inhaled drugs, potentially expanding VC interest in UK/US biopharma startups via networks like Atlas and Gimv.[1]
Kinaset is poised to advance KN-002 into broader trials and expand frevecitinib data, with next accounts due September 2026 signaling sustained operations.[2][3] Trends like targeted inhalation therapies and AI-driven drug design will shape its path, potentially amplifying influence through partnerships or Phase 2 readouts.[4][5] As a focused respiratory player, it could redefine severe asthma care, building on its expert foundation to capture a slice of the growing inhaled therapeutics market.[1][2]
Kinaset Therapeutics has raised $143.0M in total across 2 funding rounds.
Kinaset Therapeutics's investors include Anand Mehra, Henry Stusnick, 5AM Ventures, Atlas Venture, Bram Vanparys, PhD, MBA, Daniela Begolo, Pictet Alternative Advisors, Schroders Capital, Sixty Degree Capital, Vivo Capital, Willett Advisors, Kevin Bitterman.
Kinaset Therapeutics has raised $143.0M across 2 funding rounds. Most recently, it raised $103.0M Series B in January 2026.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 10, 2026 | $103.0M Series B | Anand Mehra, Henry Stusnick | 5AM Ventures, Atlas Venture, Bram Vanparys, PhD, MBA, Daniela Begolo, Pictet Alternative Advisors, Schroders Capital, Sixty Degree Capital, Vivo Capital, Willett Advisors |
| Nov 1, 2020 | $40.0M Series A | 5AM Ventures, Kevin Bitterman, Bram Vanparys, PhD, MBA |